ArticlesRituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
Introduction
Immune thrombocytopenia is caused by immune-mediated platelet destruction and impaired platelet production, causing thrombocytopenia and occasionally bleeding.1 The main goals of treatment are: first, to achieve sustained, haemostatic platelet counts to minimise the risk of bleeding; and second, to cure the patient if possible—both aims should be achieved with the fewest possible toxic effects.2, 3 Corticosteroids are the main first-line treatment for immune thrombocytopenia in adults, yielding initial response rates of 70–90%;2, 3 however, because of relapses during dose tapering or after corticosteroid discontinuation, sustained responses are reduced and occur between 30% and 80% of the time.2, 4, 5, 6 Patients who do not achieve a sustained response to corticosteroids usually need second-line treatment. Splenectomy is still recommended as the standard second-line therapy in patients with chronic immune thrombocytopenia.3 Splenectomy is an invasive procedure associated with perioperative and postoperative complications,7, 8 with no means to predict the patient's response to the procedure.9 Because of the availability of medical alternatives2 and increasing evidence of late remissions, whether spontaneous or with continuing treatment,5, 10 physicians have become more reluctant to do a splenectomy and patients are less willing to undergo splenectomy.9, 11
Of the many available second-line alternatives,2 the anti-CD20 antibody rituximab and approved thrombopoietin receptor agonists are widely used.9 Rituximab has been shown to provide initial response rates of about 60%;12 however, sustained responses lasting for more than 2 years occur in substantially fewer than 60% of patients.13, 14 Whether the administration of rituximab to patients who did not respond to corticosteroid treatment would render splenectomy or other therapeutic options superfluous is unknown. This trial aimed to assess the long-term efficacy of rituximab as a splenectomy sparing option in corticosteroid-exposed adult patients with immune thrombocytopenia.
Section snippets
Study design and patients
In this double-masked, placebo-controlled trial, we enrolled adult patients with immune thrombocytopenia10 in 14 centres in Norway, Tunisia, and France. The eligibility criteria for inclusion in the study were unsplenectomised patients with primary immune thrombocytopenia with a platelet count of less than 30 × 109 platelets per L (or 30–50 × 109 platelets per L if a higher platelet count was deemed necessary because of bleeding or concomitant anti-platelet therapy); patients who did not
Results
Between Aug 17, 2006, and June 30, 2011, we enrolled 112 patients (figure 1, table 1). Of 112 randomly assigned patients, three patients did not receive the allocated treatment and were not included in the full analysis set. Two patients in the placebo group were lost to follow-up.
Table 2 summarises the number of patients who responded to treatment and serious safety outcomes. The Kaplan-Meier estimates of cumulative incidence of overall response at 78 weeks were 81% in the rituximab group and
Discussion
To our knowledge, this trial is the first randomised placebo-controlled study to assess long-term efficacy of rituximab as a second-line treatment for immune thrombocytopenia in adults (panel). The study shows that provision of rituximab to patients not achieving a sustained response to corticosteroids does not significantly reduce the rate of treatment failure compared with placebo.
The aim of the study was to establish whether the use of rituximab would ultimately render splenectomy
References (24)
- et al.
The ITP syndrome: pathogenic and clinical diversity
Blood
(2009) - et al.
International consensus report on the investigation and management of primary immune thrombocytopenia
Blood
(2010) - et al.
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Blood
(2011) - et al.
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura
Blood
(2001) - et al.
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
Blood
(2004) - et al.
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
Blood
(2012) - et al.
Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology
Blood
(1996) - et al.
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Blood
(2012) - et al.
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Blood
(2010) - et al.
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia
Blood
(2013)
Cited by (156)
CAR-T cells for treating systemic lupus erythematosus: A promising emerging therapy
2024, Joint Bone SpinePrimary and secondary immune thrombocytopenia (ITP): Time for a rethink
2023, Blood ReviewsTreatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study
2022, Research and Practice in Thrombosis and HaemostasisPrimary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities
2024, International Journal of Rheumatology
- †
Members listed at end of paper